^
    Back
    Association details:
    Biomarker:ATM deletion
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Lynparza (olaparib) (PARP inhibitor) +
    AZD7648 (DNA PK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Nat Commun
    Title:

    AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

    Excerpt:
    Using ATM-deficient cells, we demonstrate that AZD7648, in combination with the PARP inhibitor olaparib, increases genomic instability, resulting in cell growth inhibition and apoptosis….AZD7648 induces complete tumour regression in combination with olaparib in FaDu ATM KO xenografts....
    DOI:
    10.1038/s41467-019-12836-9